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Alternative splicing is the process by
which various combinations of exons
are included in a mature mRNA, thus
allowing a single gene to encode mul-
tiple protein isoforms with potentially
different or even antagonistic properties.
Proper mRNA splicing is absolutely cru-
cial for nervous system development and
its misregulation has been demonstrated
in schizophrenia (Morikawa and Manabe,
2010). Schizophrenia is a severe and debil-
itating neuropsychiatric syndrome which
has a complex etiology and is believed to
arise from the interplay between genetic
and environmental factors. Altered expres-
sion of genes involved in early migra-
tion of neurons and glia, cell proliferation,
axonal outgrowth and synaptogenesis in
schizophrenic patients support a neurode-
velopmental model.
A transcriptome sequencing study
of the cortex of schizophrenic patients
recently revealed significant differences
in PAC1 receptor alternative splicing
(Wu et al., 2012), but the functions of
the aberrant isoforms are still unclear.
PAC1 is a G-protein-coupled recep-
tor activated by pituitary adenylate
cyclase activating polypeptide (PACAP,
Adcyap1), which is a potential schizophre-
nia susceptibility gene and whose loss of
function in mice (PACAP−/−) showed
several schizophrenia-related behaviors
(Hashimoto et al., 2007).
PACAP acts as neurotransmitter and/or
neurotrophic peptide via PAC1 (or VPAC
receptors) with a wide range of func-
tions throughout ontogenesis (e.g., prolif-
eration and survival control). In rat, eight
splice variants of the PAC1 receptor have
been identified that mainly trigger adeny-
late cyclase (AC) and/or phospholipase C
(PLC) activation.
The description of PAC1 receptor
isoforms shed light on the unresolved
pleiotropic biological functions of PACAP.
In a recent paper in The Journal of
Neuroscience, Yan et al. (2013) addressed
this question in the context of cortical neu-
rogenesis and provided compelling evi-
dence that developmental switch of PAC1
receptor mRNA isoforms accounts for
both pro- and anti-mitogenic actions of
PACAP.
Previous studies indicated that PACAP
signaling inhibits the proliferation of cor-
tical precursor cells from E13.5 onward.
In contrast, they initially found that
PACAP−/− mice exhibit reduced S-phase
labeling at E9.5 ventricular zone (VZ).
Then, Yan et al. (2013) developed a novel
culture model of young neural precur-
sors that was instrumental to define the
contribution of PAC1 receptor variants
on PACAP proliferative effects on early
neurogenesis.
Using this system, they assessed the
expression and function of PAC1 short
isoform and insert-containing hop iso-
form (PAC1 hop). These isoforms are
coupled to different transduction path-
ways (AC and AC/PLC, respectively) and
were previously shown to elicit antago-
nist effects in cortical precursors prolifer-
ation. Specific pairs of primers designed
for each PAC1 isoform showed a 24-fold
greater content of hop isoform mRNA
at E10.5, whereupon PACAP exposure
promoted G1 cyclins and G1/S-phase pro-
gression. In contrast, by E14.5, in which
PACAP exposure promoted cell cycle exit,
short isoform mRNA content was 15-fold
greater than hop.
Two intriguing questions, then, may
be formulated: (1) which RNA binding
proteins (splicing activators or repressors)
regulate the developmental switch in the
expression of PAC1 isoforms?, and (2)
Are these RNA-binding proteins misreg-
ulated in neurodevelopmental disorders?
Interestingly, A2BP1, a sequence-specific
RNA-binding protein, could be a start-
ing point to answer these questions, as
it promotes the generation of PAC1-hop
mRNA isoform (Amir-Zilberstein et al.,
2012). Moreover, A2BP1 is differentially
expressed throughout cortical develop-
ment and de novo copy number mutations
of this gene contribute to the genetic com-
ponent of schizophrenia (Melhem et al.,
2011).
In addition, using a shRNA specific
to PAC1hop, the authors further demon-
strated that PACAP pro-mitogenic effect
requires PAC1hop expression. The general
notion is that upon PACAP binding to
PAC1hop, the PLC transduction pathway
is activated and two second messengers
are then generated. Diacylglycerol (DAG)
leads to PKC activation, whereas inos-
itol triphosphate (IP3) triggers calcium
(Ca2+) release from endoplasmic reticu-
lum stores. Both stimuli are well-known
stimulators of cell proliferation in multi-
ple systems. Consistently, a PLC-specific
inhibitor blocked PACAP pro-mitogenic
effect.
It is noteworthy that PACAP was
able to trigger Ca2+ influx and PKC
activation only at E10.5, but not at
E14.5, even though PAC1hop expres-
sion changed little between these stages.
In conclusion, the authors showed that
the proper balance between PAC1-short
and -hop isoforms determines the acti-
vation of PLC and consequently the
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pro- or anti-mitogenic actions of PACAP
signaling.
Overall, the study by Yan et al. (2013)
in combination with other recent reports
has provided novel insights into how mis-
regulation of PAC1 alternative splicing
could contribute to the risk of devel-
oping schizophrenia, not only by affect-
ing embryonic neurogenesis, but also by
impairing proliferation and differentiation
of adult stem cells. Accordingly, Reif et al.
(2006) demonstrated a reduction in the
amount of hippocampal neural stem cells
in post-mortem schizophrenic brains (Reif
et al., 2006), raising the idea that this could
explain the reduction of hippocampal vol-
ume and the correlation with several cog-
nitive deficits. PAC1 is also expressed in the
classical neurogenic regions of the adult
mouse brain, namely the VZ of the lat-
eral ventricle and the hippocampal dentate
gyrus, and its activation promotes neu-
ral stem cell proliferation (Mercer et al.,
2004).
Although significant progress has been
made toward the understanding of how
PACAP and PAC1 contributes to the
pathogenesis of schizophrenia, little is
known about the expression and function
of PAC1 isoforms in the cortex and in the
neurogenic regions of patients. Moreover,
the concept that developmental transition
in the expression of PAC1 splice isoforms
leads to PACAP antagonistic effects on
neurogenesis suggests a possible compen-
sation mechanism that could mask more
severe symptoms caused by deregulated
neurogenesis in PACAP knockout mice.
Therefore, development of transgenic ani-
mal models to mimic alterations in PAC1
alternative splicing found in schizophrenia
would help to unveil a possible associa-
tion between PACAP-PAC1 signaling and
schizophrenia.
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